Zimmer Biomet (ZBH) Stock
Global maker of joint replacement and spinal implants. Here's the price, business snapshot, and what's worth knowing about Zimmer Biomet in August 2026.
Zimmer Biomet Holdings, Inc. (ZBH) is a global medical‑device company specialising in musculoskeletal healthcare — primarily joint replacement, spinal and dental solutions. With a market capitalisation around $20.3bn, it serves hospitals, surgeons and clinics through product sales, aftermarket services and implants. Key growth drivers include ageing populations, increasing demand for elective orthopaedic procedures and geographic expansion in emerging markets. Investors should watch procedure volumes, product mix, pricing pressure, merger and acquisition activity and reimbursement trends — these affect revenue and margins. The business is also exposed to regulatory, litigation and supply‑chain risks that can affect performance. Financially, margins can improve with scale and operational efficiency, but outcomes vary by cycle and region. This summary is educational and not personalised investment advice; shares can fall as well as rise. Consider your objectives and risk tolerance or consult a regulated adviser before acting.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts suggest holding Zimmer Biomet's stock with a target price of $120.26, indicating limited growth potential.
Financial Health
Zimmer Biomet is performing well with strong profits and cash flow, indicating solid financial health.
Dividend
Zimmer Biomet's low dividend yield of 0.62% may not attract dividend-seeking investors. If you invested $1000 you would be paid $6.20 a year in dividends (based on the last 12 months).
Why You’ll Want to Watch This Stock
Aging population demand
An older population supports long‑term demand for joint replacements and related care, though procedure cycles and reimbursement can cause variability.
Global market exposure
Broad geographic presence can fuel growth as emerging markets adopt advanced care, but it also brings currency, regulatory and supply‑chain risks.
R&D and margins
Innovation and product mix can lift margins over time, yet investment cycles and competitive pricing pressure mean outcomes are uncertain.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
